Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A.

Cancer Discov. 2016 Oct;6(10):1106-1117. Epub 2016 Aug 12.

2.

Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.

McKeegan EM, Ansell PJ, Davis G, Chan S, Chandran RK, Gawel SH, Dowell BL, Bhathena A, Chakravartty A, McKee MD, Ricker JL, Carlson DM, Ramalingam SS, Devanarayan V.

Lung Cancer. 2015 Nov;90(2):296-301. doi: 10.1016/j.lungcan.2015.09.011. Epub 2015 Sep 15.

PMID:
26424209
3.

Reply to M. Bouattour et al.

Cainap C, McKee MD, Ricker JL.

J Clin Oncol. 2015 Aug 1;33(22):2486. doi: 10.1200/JCO.2015.61.6730. Epub 2015 Jun 1. No abstract available. Erratum in: J Clin Oncol. 2017 Aug 1;35(22):2590.

PMID:
26033815
4.

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ.

Invest New Drugs. 2015 Aug;33(4):870-80. doi: 10.1007/s10637-015-0242-6. Epub 2015 May 2.

5.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA.

J Clin Oncol. 2015 Feb 10;33(5):433-41. doi: 10.1200/JCO.2014.55.7173. Epub 2015 Jan 5.

6.

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S.

J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 Dec 8. Erratum in: J Clin Oncol. 2017 Aug 1;35(22):2590.

7.

Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.

O'Neil BH, Cainap C, Van Cutsem E, Gorbunova V, Karapetis CS, Berlin J, Goldberg RM, Qin Q, Qian J, Ricker JL, Fischer J, McKee MD, Carlson DM, Kim TW.

Clin Colorectal Cancer. 2014 Sep;13(3):156-163.e2. doi: 10.1016/j.clcc.2014.04.001. Epub 2014 Jun 23.

PMID:
25066269
8.

Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.

Xiong H, Chiu YL, Ricker JL, LoRusso P.

Cancer Chemother Pharmacol. 2014 Jul;74(1):55-61. doi: 10.1007/s00280-014-2475-z. Epub 2014 May 9.

PMID:
24810181
9.

Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors.

Chiu YL, Lorusso P, Hosmane B, Ricker JL, Awni W, Carlson DM.

Cancer Chemother Pharmacol. 2014 Jan;73(1):213-7. doi: 10.1007/s00280-013-2351-2. Epub 2013 Nov 16.

10.

Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.

Chiu YL, Carlson DM, Pradhan RS, Ricker JL.

Clin Ther. 2013 Nov;35(11):1770-7. doi: 10.1016/j.clinthera.2013.09.002. Epub 2013 Oct 2.

PMID:
24094464
11.

Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.

Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP.

Cancer. 2013 Jan 15;119(2):380-7. doi: 10.1002/cncr.27758. Epub 2012 Jul 25.

12.

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.

Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD.

Eur J Cancer. 2011 Dec;47(18):2706-14. doi: 10.1016/j.ejca.2011.09.002. Epub 2011 Nov 10.

13.

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.

Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA.

J Thorac Oncol. 2011 Aug;6(8):1418-25. doi: 10.1097/JTO.0b013e318220c93e.

14.

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.

Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ.

Clin Lymphoma Myeloma. 2009 Dec;9(6):412-6. doi: 10.3816/CLM.2009.n.082.

PMID:
19951879
15.

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.

Watanabe T, Kato H, Kobayashi Y, Yamasaki S, Morita-Hoshi Y, Yokoyama H, Morishima Y, Ricker JL, Otsuki T, Miyagi-Maesima A, Matsuno Y, Tobinai K.

Cancer Sci. 2010 Jan;101(1):196-200. doi: 10.1111/j.1349-7006.2009.01360.x. Epub 2009 Sep 10.

16.

Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C.

Mol Cancer Ther. 2008 Jul;7(7):1949-60. doi: 10.1158/1535-7163.MCT-07-2046.

17.

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.

Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schöffski P.

Invest New Drugs. 2008 Oct;26(5):483-8. doi: 10.1007/s10637-008-9131-6. Epub 2008 Apr 19.

PMID:
18425418
18.

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD.

Ann Oncol. 2008 May;19(5):964-9. doi: 10.1093/annonc/mdn031. Epub 2008 Feb 21.

PMID:
18296419
19.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM.

Blood. 2008 Feb 1;111(3):1060-6. Epub 2007 Oct 25.

20.

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.

Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR.

Invest New Drugs. 2008 Feb;26(1):81-7. Epub 2007 Oct 25.

PMID:
17960324
21.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M.

J Clin Oncol. 2007 Jul 20;25(21):3109-15. Epub 2007 Jun 18.

PMID:
17577020
22.

Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck.

Allen CT, Ricker JL, Chen Z, Van Waes C.

Head Neck. 2007 Oct;29(10):959-71. Review.

PMID:
17405170
23.

A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.

Rubin EH, Agrawal NG, Friedman EJ, Scott P, Mazina KE, Sun L, Du L, Ricker JL, Frankel SR, Gottesdiener KM, Wagner JA, Iwamoto M.

Clin Cancer Res. 2006 Dec 1;12(23):7039-45.

24.

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR.

Blood. 2007 Jan 1;109(1):31-9. Epub 2006 Sep 7. Erratum in: Blood. 2007 Jun 15;109(12):5086.

25.
26.
27.

Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma.

Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS Jr, Van Waes C.

Cancer Res. 2004 Sep 15;64(18):6511-23. Erratum in: Cancer Res. 2004 Nov 1;64(21):8130-2.

28.

Multiorgan mRNA misexpression in murine autosomal recessive polycystic kidney disease.

Gattone VH, Ricker JL, Trambaugh CM, Klein RM.

Kidney Int. 2002 Nov;62(5):1560-9.

29.

c-myc antisense oligonucleotide treatment ameliorates murine ARPKD.

Ricker JL, Mata JE, Iversen PL, Gattone VH.

Kidney Int. 2002 Jan;61(1 Suppl):S125-31.

30.

Development of autosomal recessive polycystic kidney disease in BALB/c-cpk/cpk mice.

Ricker JL, Gattone VH 2nd, Calvet JP, Rankin CA.

J Am Soc Nephrol. 2000 Oct;11(10):1837-47.

Supplemental Content

Loading ...
Support Center